These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

853 related articles for article (PubMed ID: 26755709)

  • 1. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
    Viardot A; Goebeler ME; Hess G; Neumann S; Pfreundschuh M; Adrian N; Zettl F; Libicher M; Sayehli C; Stieglmaier J; Zhang A; Nagorsen D; Bargou RC
    Blood; 2016 Mar; 127(11):1410-6. PubMed ID: 26755709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of blinatumomab: a real world data.
    Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
    Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
    Kiyoi H; Morris JD; Oh I; Maeda Y; Minami H; Miyamoto T; Sakura T; Iida H; Tuglus CA; Chen Y; Dos Santos C; Kalabus J; Anderson A; Hata T; Nakashima Y; Kobayashi Y
    Cancer Sci; 2020 Apr; 111(4):1314-1323. PubMed ID: 31971321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
    J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
    JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
    Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
    Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
    Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
    Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
    Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
    Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Folan SA; Rexwinkle A; Autry J; Bryan JC
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
    Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
    Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
    Topp MS; Gökbuget N; Zugmaier G; Klappers P; Stelljes M; Neumann S; Viardot A; Marks R; Diedrich H; Faul C; Reichle A; Horst HA; Brüggemann M; Wessiepe D; Holland C; Alekar S; Mergen N; Einsele H; Hoelzer D; Bargou RC
    J Clin Oncol; 2014 Dec; 32(36):4134-40. PubMed ID: 25385737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
    Zinzani PL; Minotti G
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C; Thomas X
    Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy.
    Kuchimanchi M; Zhu M; Clements JD; Doshi S
    Br J Clin Pharmacol; 2019 Apr; 85(4):807-817. PubMed ID: 30645768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
    Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.